- Home
- TSI vs PROF Comparison
TSI vs PROF Comparison
Compare TSI & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- PROF
- Stock Information
- Founded
- TSI 1987
- PROF N/A
- Country
- TSI United States
- PROF Canada
- Employees
- TSI N/A
- PROF N/A
- Industry
- TSI Investment Managers
- PROF Medical/Dental Instruments
- Sector
- TSI Finance
- PROF Health Care
- Exchange
- TSI Nasdaq
- PROF Nasdaq
- Market Cap
- TSI 241.8M
- PROF 186.3M
- IPO Year
- TSI N/A
- PROF N/A
- Fundamental
- Price
- TSI $5.01
- PROF $7.24
- Analyst Decision
- TSI
- PROF Strong Buy
- Analyst Count
- TSI 0
- PROF 2
- Target Price
- TSI N/A
- PROF $11.40
- AVG Volume (30 Days)
- TSI 106.8K
- PROF 105.6K
- Earning Date
- TSI 01-01-0001
- PROF 11-07-2024
- Dividend Yield
- TSI 7.46%
- PROF N/A
- EPS Growth
- TSI N/A
- PROF N/A
- EPS
- TSI N/A
- PROF N/A
- Revenue
- TSI N/A
- PROF $8,984,000.00
- Revenue This Year
- TSI N/A
- PROF $56.61
- Revenue Next Year
- TSI N/A
- PROF $160.87
- P/E Ratio
- TSI N/A
- PROF N/A
- Revenue Growth
- TSI N/A
- PROF 39.35
- 52 Week Low
- TSI $4.48
- PROF $6.88
- 52 Week High
- TSI $4.87
- PROF $11.42
- Technical
- Relative Strength Index (RSI)
- TSI 50.11
- PROF 40.10
- Support Level
- TSI $4.98
- PROF $7.00
- Resistance Level
- TSI $5.07
- PROF $7.40
- Average True Range (ATR)
- TSI 0.03
- PROF 0.40
- MACD
- TSI -0.00
- PROF -0.07
- Stochastic Oscillator
- TSI 33.33
- PROF 15.52
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.